Table of contents


On 11 December 2001, orphan designation (EU/3/01/075) was granted by the European Commission to Ligand Pharmaceuticals UK Ltd, United Kingdom, for denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

The sponsorship was transferred to Esai Ltd, United Kingdom, in March 2007.

The sponsorship was transferred to Eisai GmbH, Germany in October 2018.

The sponsor’s address was updated in August 2020.

Key facts

Active substance
Denileukin diftitox
Disease / condition
Treatment of cutaneous T-cell lymphoma
Date of first decision
EU designation number

Sponsor's contact details

Edmund-Rumpler-Straße 3
60549 Frankfurt am Main

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating